Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc.
Your view on GLSI
Overview
What the company does, where it operates, and who runs it.
About Greenwich LifeSciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Snehal S. Patel
- Headquarters
- Building 14, Stafford, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Snehal S. Patel
- Headquarters
- Building 14, Stafford, TX, US
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Greenwich LifeSciences, Inc., and the rating behind it. GLSI last traded at $15.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Greenwich LifeSciences, Inc.. Starting points for Greenwich LifeSciences, Inc.: EPS -$1.48, beta 1.46 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Greenwich LifeSciences, Inc.. Greenwich LifeSciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Greenwich LifeSciences, Inc.. Trailing twelve-month EPS for Greenwich LifeSciences, Inc. stands at -$1.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Greenwich LifeSciences, Inc.. Greenwich LifeSciences, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Greenwich LifeSciences, Inc. valued side by side against its closest peers. Greenwich LifeSciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Greenwich LifeSciences, Inc., and how their positions are changing. At a $226.8M market value, institutional positions materially move Greenwich LifeSciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Greenwich LifeSciences, Inc. executives and directors. Shares of Greenwich LifeSciences, Inc. have traded between $7.88 and $15.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Greenwich LifeSciences, Inc.. Greenwich LifeSciences, Inc. is a $226.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Greenwich LifeSciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Greenwich LifeSciences, Inc.. Coverage tracks Greenwich LifeSciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.